Clinical trial NCT04379271: A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Official title: A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: COVID-19
Lead sponsor: Immunic AG
Sponsor class: INDUSTRY
Collaborators: name: FGK Clinical Research GmbH
First posted: 2020-05-07
Enrollment: 234
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: double-blind, placebo-controlled, randomized, parallel-group trial
Primary purpose: TREATMENT

Brief summary: At present there is no approved drug treatment for Covid-19. In this study we plan to investigate if an experimental drug called IMU-838 (vidofludimus calcium) can improve your symptoms, prevent worsening that would initiate further treatments such as ventilation, and can lower your virus number if given in addition to your doctor's choice of standard therapy. We will also test if IMU-838 has any side effects and measure the level of IMU 838 in your blood.

Experimental drug means that it is not yet authorized for marketing in your country. To date approximately 600 individuals have received IMU-838 (or a drug similar to IMU-838 that contains the same active substance as IMU-838) in research studies.

Detailed description: The trial consists of a Phase 2 proof-of-concept phase (Part 1) with the option to extend enrollment (without interruption) to Phase 3 (Expansion Phase, Part 2).

This trial is a multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to evaluate the safety and efficacy of IMU-838 as addition to investigator's choice of SoC treatment in patients with COVID-19. Eligible patients will be centrally randomized 1:1 to twice-daily (BID) oral 22.5 mg IMU-838 (45 mg/day + SoC) or placebo (+ SoC). Randomization will be stratified by age (\< or \>=65 years) and antiviral therapy (no antivirals, Hydroxychloroquine and Chloroquine, all other antivirals).

Adaptive sequential trial design and overall trial design

The trial uses an adaptive sequential design. An IDMC will review unblinded data and provide the Sponsor with recommendations regarding modifications of sample size and trial conduct.

A 1st interim analysis (IA1) will be performed after approximately 200 patients have completed the trial (either as scheduled or prematurely), while enrollment continues. If no activity of IMU 838 is observed by the IDMC in this IA, further patient enrollment will be stopped, and a final analysis of Part 1 will be performed (FA1). It is expected that the final analysis of Part 1 will include approximately 230 patients. If the IA1 results indicate activity of IMU-838 in COVID-19, the trial may be extended to Part 2 with a revised sample size derived by the IDMC based on IA1 results and with possible other trial adjustments. If the trial is extended into Part 2, a 2nd IA (IA2) is planned after approximately two-thirds of patients (based on the overall global sample size \[Part 1 and Part 2 combined\]) have been enrolled to potentially adjust sample size and other trial features if needed. The final analysis of the trial (FA2) will then be done after all patients have completed Part 2.

In addition, an early interim safety analysis will be performed and evaluated by the IDMC after 30 patients have been enrolled to assess unblinded safety data. Further safety analyses can be initiated at any time by the IDMC or Sponsor when new safety signals are identified within this or other trials of IMU-838.

Screening

Patients can be screened for a maximum of 2 days (from Day -2 to Day 0) and eligible patients will be randomized on Day 0 and treated with IMP + SoC for 14 days. It is encouraged to screen potential participants immediately at the day of hospitalization (including informed consent, assessment of inclusion/exclusion criteria, screening laboratory tests all done locally, assessment of clinical and blood gas criteria) and randomize patients on the same day (Day 0). To assess eligibility criteria, existing local laboratory values obtained within 48 hours of randomization can also be used, except for testing of positive status of SARS-CoV-2 infection where a 4-day window is allowed.

IMP administration should start as quickly as possible after randomization and first IMP intended to be given in the evening of the screening day (Day 0).

Blinded Treatment period (Day 0 to Day 13) and Day 14 (end-of-treatment)

The first dose of IMP (2 tablets) should always be given on Day 0 (allowed range for first dose: 12:00 noon on Day 0 to 02:00 a.m.). All further IMP doses are 1 tablet each in the morning and evening. Information about the status and patient care are continuously obtained and documented once or twice daily.

After the last IMP dose in the evening of Day 13, the end-of-treatment assessments will be done on Day 14. Blood sampling for IMU-838 trough values must be performed in the morning around the time the morning dose was usually taken by the respective patient. Patients may then continue to receive SoC without any further restrictions on concomitant medications as during the 14-day BT period .

Day 28 Visit (EoS)

The patient should return for the final trial visit on Day 28 (EoS). If IMP is prematurely discontinued for any reason, the EoS visit should always be conducted on Day 28 and no earlier EoS should be performed. If patients withdraw from IMP prematurely, they should be encouraged to allow the EoS visit as part of the follow-up. If the patient dies during the trial, the investigator should indicate that this visit was not performed. However, even if no EoS visit was performed, information about patient status should be reported on the EoS page in the case report form. If the patient refuses any EoS visit or the patient is lost to follow-up, it is permissive in this trial that the investigator contacts the patient, the family of the patient or the referring physician by phone or email to obtain status of life information, or is able to search in registers or publicly available information for such status of life information.

Eligibility criteria: Inclusion Criteria:

1. Male or female patients at least 18 years old (may be extended to include also children 12 years or older after the 1st interim analysis)
2. Admitted to the hospital or other medical in-patient treatment facility for treatment of COVID-19 The hospitalization needs to be for medical reasons (treatment of COVID-19 disease) and cannot be for social reasons or due to housing insecurity.

   For US sites only: If the investigator would commonly hospitalize the patient but for healthcare resource reasons decides to treat the patient in a specially designed out-patient setting, then such patients are also allowed to enter the trial (please note that in this case the patient would be counted as clinical status category 3). The investigator then must assure that the patient has at least a twice daily assessment by qualified trial personnel and all laboratory assessments can be adequately performed as per protocol. The Sponsor reserves the right to discontinue this option via administrative letter if such assurances cannot be met by any site.
3. SARS-CoV-2 infection confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) test in a nasopharyngeal, oropharyngeal or respiratory sample at ≤4 days before randomization
4. Moderate COVID-19 disease defined as fulfilling clinical status category 3 or 4 on the WHO 9-point ordinal scale \[21\]:

   * Category 3: Hospitalized (see note above for US only), virus-positive, no oxygen therapy with the following conditions:
   * The hospitalization needs to be for medical reasons (treatment of COVID-19 disease) and cannot be for social reasons or due to housing insecurity
   * Category 4: Hospitalized, virus-positive, oxygen by mask or nasal prongs (excluding high-flow oxygen therapy) with the following conditions:
   * Peripheral capillary oxyhemoglobin saturation (SpO2) \>92% at maximum of 6 liters oxygen flow per minute
   * Stable respiratory rate ≤30 breaths/min at maximum of 6 liters oxygen flow per minute
5. Presence of at least 1 symptom characteristic for COVID-19 disease i.e., fever, cough or respiratory distress
6. Willingness and ability to comply with the protocol
7. Written informed consent given prior to any trial-related procedure
8. For women of childbearing potential: Application of a highly effective method of birth control (failure rate less than 1% per year when used consistently and correctly) together with a barrier method between trial consent and 30 days after the last intake of the IMP.

   Highly effective forms of birth control are those with a failure rate less than 1% per year and include:
   * oral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraceptives associated with inhibition of ovulation
   * oral, injectable, or implantable progestogen-only hormonal contraceptives associated with inhibition of ovulation
   * intrauterine device or intrauterine hormone-releasing system
   * bilateral tubal occlusion
   * vasectomized partner (i.e., the patient's male partner underwent effective surgical sterilization before the female patient entered the clinical trial and is the sole sexual partner of the female patient during the clinical trial)
   * sexual abstinence (acceptable only if it is the patient's usual form of birth control/lifestyle choice; periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are no acceptable methods of contraception)

   Barrier methods of contraception include:
   * Condom
   * Occlusive cap (diaphragm or cervical/vault caps) with spermicidal gel/film/cream/suppository
9. Male patients must agree not to father a child or to donate sperm starting at Screening, throughout the clinical trial and for 30 days after the last intake of the IMP. Male patients must also

   * abstain from sexual intercourse with a female partner (acceptable only if it is the patient's usual form of birth control/lifestyle choice), or
   * use adequate barrier contraception during treatment with the IMP and until at least 30 days after the last intake of the IMP, and
   * if they have a female partner of childbearing potential, the partner should use a highly effective contraceptive method as outlined in inclusion criterion 8
   * if they have a pregnant partner, they must use condoms while taking the IMP to avoid exposure of the fetus to the IMP

Exclusion Criteria:

Underlying disease-related exclusion criteria

1. Involvement in the trial is not in the patient's best interest according to the investigator's decision, including the presence of any condition that would, in the assessment of the investigator, not allow the protocol to be followed safely Note: The investigator should particularly consider exclusion of patients at increased risk for serious or fatal AEs in case of worsening of the pulmonary perfusion. This includes, but is not limited to, pre-existing pulmonary hypertension, severe chronic respiratory disease, severely increased risk for thromboembolic complications and moderate to severe left ventricular ejection fraction (LVEF) dysfunction. In addition, other known risk factors of highest risk of mortality in COVID-19 patients should be considered.
2. Presence of respiratory failure, shock, and/or combined failure of other organs that requires ICU monitoring in the near foreseeable future
3. Critical patients whose expected survival time \<48-72 hours
4. Presence of the following laboratory values at screening:

   * White blood cell count (WBC) \<1.0 x 109/L
   * Platelet count \<100,000/mm³ (\<100 x 109/L)
   * Total bilirubin\>2 x ULN
   * Alanine aminotransferase (ALT) or gamma glutamyl transferase (GGT) \>5 x ULN
5. Participation in any other interventional clinical trial
6. Hospitalization primarily for other reasons than COVID-19 (including primarily for concomitant conditions during ongoing SARS-CoV-2 infection)
7. Anticipated transport to a different hospital or institution, in particular when such transport is anticipated for pending ECMO or RRT treatment
8. Clinical suspicion of a bacterial superinfection at Screening IMP-related exclusion criteria
9. Patients who cannot take drugs orally
10. Allergic or hypersensitive to the IMP or any of the ingredients
11. Use of the following concomitant medications is prohibited from Screening to end of treatment with IMP in this trial (up to Day 14) if not indicated otherwise in this protocol:

    * Concurrent use of any mycophenolate mofetil or of methotrexate exceeding 17.5 mg weekly
    * Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad (Zurampic™) as well as uricosuric drugs such as probenecid
    * Current treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafenib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib
    * Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogs
    * Use of rosuvastatin at daily doses higher than 10 mg
    * Arbidol and Colchicine
    * Any use of other DHODH inhibitors, including teriflunomide (Aubagio™) or leflunomide (Arava™)
    * Chloroquine and Hydroxychloroquine during the entire trial unless taken for indicated use before entering the trial
12. Use of any investigational product within 8 weeks or 5x the respective half-life before the date of informed consent, whichever is longer, and throughout the duration of the trial General exclusion criteria
13. Patients who have a "do not intubate" or "do not resuscitate" order (unless the patient waives in writing this order and will allow intubation for the duration of the trial period)
14. Patients with end-stage liver disease (Child Pugh C score)
15. History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association \[NYHA\] class 3 or 4) Note: NYHA class 3: Cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain. NYHA class 4: Cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
16. Legal incapacity, limited legal capacity, or any other condition that makes the patient unable to provide consent for the trial
17. Pregnant or breastfeeding
18. An employee of an investigator or Sponsor or an immediate relative of an investigator or Sponsor
19. Patients institutionalized due to judicial order

Primary outcomes:
measure: Proportion of Patients Without Any Need for INV Until EoS
timeFrame: Throughout the Study (Day 0 to Day 28)
Secondary outcomes:
measure: Days in ICU Department
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: All Cause Mortality (ITT Approach)
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Time to Clinical Improvement
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days of Hospitalization
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Patients Free of Renal-replacement Therapy (RRT)* Until EoS
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Patients Required ECMO Until EoS
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Patients Free of INV Until Day 14*
timeFrame: Throughout the Study (Day 0 to Day 14 )
measure: Patients Free of RRT
timeFrame: Day 0 to Day 14
measure: Number of Patients Free of ECMO
timeFrame: Day 0 to Day 14
measure: Patients With Improvement of at Least 2 Points (From Randomization) on the 9-category WHO Ordinal scale1
timeFrame: on Days 6, 14, and 28
measure: Patients With Auxiliary Oxygen Therapy (Including All Types of Oxygen Therapy)
timeFrame: on Days 6, 14, and 28
measure: Patients With Clinical Recovery
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Patients With Clinical Recovery
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Patients With Clinical Improvement or Live Discharge From Hospital Without Oxygen Supplementation
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Percentage of Participants With WHO Status<=2
timeFrame: on Days 6, 14, and 28
measure: Duration of INV
timeFrame: Throughout the Study (Day 0 to Day 28 )
measure: Days on ECMO
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days on RRT
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days of Auxiliary Oxygen Therapy
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days of Hospitalization
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Participants With ICU Admission
timeFrame: on Days 6, 14, and 28
measure: Probability of Death
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days to INV
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days to RRT
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days to ECMO
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Days to INV, RRT and ECMO
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Probability of ICU Admission
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Cumulative Dose
timeFrame: Day 0 to day 14
measure: Time to Clinical Recovery
timeFrame: Throughout the Study (Day 0 to EoS [Day 27 up to Day 42])
measure: Plasma Levels of IMU-838
timeFrame: on Days 0, 1, 2, 3, 6, 14, and 28
measure: Correlation of Trough Levels (Quartiles) to Selected Clinical Outcomes
timeFrame: Trough levels at Day 14; Clinical outcome: Day 0 to EoS (EoS = Day 27 up to Day 42)
measure: Number of Participants With Adverse Events (AEs) and Serious AEs
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Vital Signs: Height
timeFrame: at Baseline
measure: Vital Signs: Weight
timeFrame: at Baseline
measure: Vital Signs: Body Temperature (ºC)
timeFrame: at Baseline
measure: Albumin Concentration at Various Time Points
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Hematocrit Ratio at Various Time Points
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Urine Creatinine at Various Time Points
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Temperature
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: D-dimer
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Lactate Dehydrogenase (LDH)
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: C-reactive Protein
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Troponin I
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Procalcitonin
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Correlation of Time to Clinical Improvement With Quartiles of D-Dimer Blood Levels at Day 6
timeFrame: D-Dimer levels at Day 6; Clinical outcome: Day 0 to EoS (EoS = Day 27 up to Day 42)
measure: Changing in Log 10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples at Various Time Points
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Mean Viral Load - log10 Copies in Spontaneous Sputum and Nasopharyngeal Swab Samples
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Number of Participants With 2 Consecutive Negative SARS-CoV-2 Reverse Transcriptase Polymerase Chain Reaction Tests at Least 24 Hours Apart
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Rate of Conversion to a Negative SARS-CoV-2 (Qualitative) Test
timeFrame: on Day 28
measure: Time to Conversion to a Negative SARS-CoV-2 (Qualitative) Test
timeFrame: Throughout the Study (Day 0 to Day 28)
measure: Interleukin (IL)-17
timeFrame: Day 0, 6, 14 and Day 28
measure: Interleukin (IL)-1ß
timeFrame: Day 0, 6, 14 and Day 28
measure: Interleukin (IL)-6
timeFrame: Day 0, 6, 14 and 28
measure: Interferon Gamma (IFNγ)
timeFrame: Day 0, 6, 14 and 28
measure: Tumor Necrosis Factor Alpha
timeFrame: Day 0, 6, 14 and 28
measure: Immunoglobulin (Ig)A and/or IgG Antibodies Against SARS-CoV-2
timeFrame: Day 6, 14 and 28
Other outcomes:
Locations:
city: Sofia
country: Bulgaria
facility: Military Medical Academy, Clinic of Infectious Diseases
city: Sofia
country: Bulgaria
facility: UMHATEM N.I.Pirogov, Clinic of internal diseases
city: Frankfurt
country: Germany
facility: University Hospital Frankfurt, Infectious Diseases
city: Hannover
country: Germany
facility: Clinic of the Hannover Medical School, Pneumology Clinic
Study officials:
References:
citation: Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, Placinta G, Kohlhof H, Vitt D, Peelen E, Mihajlovic J, Muehler AR. Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. Infect Dis Ther. 2022 Dec;11(6):2159-2176. doi: 10.1007/s40121-022-00690-0. Epub 2022 Oct 15.